What Is Seasonal Depression? Symptoms and Treatments

What Exactly Is Seasonal Depression?

Seasonal Affective Disorder is not simply "feeling a little down in winter." It is a formally recognized subtype of major depressive disorder (MDD) in the DSM-5, defined by at least two consecutive years of depressive episodes that begin and remit at the same time each year, with full recovery between episodes. A 2022 review in JAMA Psychiatry estimated that SAD affects approximately 5% of the U.S. Adult population and accounts for roughly 10% of all depression diagnoses (1).

The condition is not a personal failing or simple laziness. The brain chemistry changes are measurable.

The Winter-Onset vs. Summer-Onset Distinction

Most people encounter winter-onset SAD, which begins in October or November and remits by March or April. A less common summer-onset variant exists, triggered by heat and extended light hours, but it represents fewer than 10% of SAD cases in clinical samples. All evidence in this article refers to winter-onset SAD unless noted otherwise (2).

Where SAD Sits in the DSM-5

The DSM-5 codes SAD as Major Depressive Disorder with a "Seasonal Pattern" specifier. To qualify, a patient must have had depressive episodes restricted to a particular time of year for at least two years, with no non-seasonal major depressive episodes occurring during that period. Clinicians distinguish it from situational low mood by the consistency of its seasonal timing and the full inter-episode recovery (3).

What Causes Seasonal Depression?

Three biological mechanisms explain most of the evidence for SAD, and they interact rather than operate in isolation.

Circadian Rhythm Disruption

Reduced winter daylight delays the body's central clock (the suprachiasmatic nucleus), shifting melatonin secretion into waking hours. A landmark study by Lewy et al. Published in the Proceedings of the National Academy of Sciences found that SAD patients showed a measurable phase delay in their dim-light melatonin onset (DLMO) compared with non-SAD controls, and that morning bright light corrected this delay and reduced depressive symptoms (4).

Serotonin Transporter Overactivity

People with SAD appear to have higher expression of the serotonin transporter (SERT) during winter months, which clears serotonin from synapses more rapidly than in matched controls. A PET imaging study (N=88) published in Archives of General Psychiatry documented significantly elevated SERT binding potential in SAD patients in autumn versus summer, a finding absent in healthy controls (5).

Vitamin D Insufficiency as a Contributing Factor

Vitamin D receptors are expressed throughout mood-regulating brain regions. Observational data from the U.S. National Health and Nutrition Examination Survey (NHANES) show an inverse relationship between serum 25(OH)D levels and depressive symptoms, though causality in SAD specifically remains under investigation (6). Vitamin D supplementation alone is not considered a first-line treatment, but clinicians commonly screen for deficiency in SAD patients.

Recognizing the Symptoms of Seasonal Depression

SAD shares core symptoms with non-seasonal MDD but has a distinct symptom profile that clinicians use to differentiate it from other mood disorders.

Core Depressive Symptoms

Patients consistently report persistent low mood or empty feeling lasting most of the day, loss of interest in previously enjoyed activities, difficulty concentrating, and feelings of hopelessness. These symptoms meet the general MDD criteria outlined in DSM-5 and reviewed in the APA's 2010 practice guidelines (7).

Atypical Features Specific to Winter SAD

Unlike classic MDD, which often presents with insomnia and appetite loss, winter-onset SAD frequently shows atypical features:

• Hypersomnia. Patients sleep 10 or more hours per night and still feel unrefreshed.
• Hyperphagia and carbohydrate craving. Appetite increases, particularly for starchy or sweet foods.
• Leaden paralysis. Heavy, leaden feelings in the arms and legs, even without physical exertion.
• Social withdrawal. Pulling back from relationships and social activities.
• Weight gain. Average winter weight gain in SAD patients is 2 to 5 kg in observational studies (8).

These atypical features are notable because they mirror hibernation physiology and likely reflect the same melatonin/circadian dysregulation described above.

Screening Tools Clinicians Use

The Patient Health Questionnaire-9 (PHQ-9) is used broadly for depression screening. For SAD specifically, many clinicians add the Seasonal Pattern Assessment Questionnaire (SPAQ), a 24-item self-report that captures the degree to which mood and behavior vary by season. A Global Seasonality Score (GSS) above 11 on the SPAQ has a sensitivity of roughly 72% and specificity of 97% for SAD in general population samples (9).

Who Is at Risk for Seasonal Depression?

Several patient characteristics raise SAD risk substantially above the population baseline.

Latitude and Light Exposure

SAD prevalence rises with distance from the equator. Studies comparing Florida (latitude 25 to 31°N) with Alaska (55 to 65°N) found SAD rates of 1.4% versus 9.2%, respectively, making latitude one of the strongest ecological predictors of disorder prevalence (10).

Sex and Age

Women are diagnosed with SAD approximately three to four times more often than men, though the sex gap narrows after age 50. Mean age of onset is the mid-20s. A family history of any mood disorder approximately doubles individual risk (11).

Shift Workers and Remote Workers

People working night shifts or spending daytime hours in windowless environments get less natural light exposure even at mid-latitudes, which may increase SAD susceptibility. This population has received less study than residential cohorts, but clinical guidance from the American Academy of Sleep Medicine addresses circadian disruption in shift workers (12).

How Is Seasonal Depression Diagnosed?

No blood test or imaging study confirms SAD. Diagnosis is clinical, based on the DSM-5 criteria plus careful history-taking to rule out other causes of seasonal mood changes, including hypothyroidism, bipolar II disorder, and substance use.

Key Differential Diagnoses

Hypothyroidism mimics SAD closely. Fatigue, weight gain, cognitive slowing, and low mood appear in both conditions, and thyroid dysfunction peaks in winter. A TSH level and free T4 should be part of the initial workup in any patient presenting with suspected SAD. The American Thyroid Association recommends TSH screening when depressive symptoms coexist with weight gain and cold intolerance (13).

Bipolar II is equally important to exclude because antidepressants given without a mood stabilizer to bipolar patients may trigger hypomania or cycling. Up to 25% of patients initially diagnosed with recurrent MDD are later reclassified as bipolar spectrum after prospective follow-up (14).

The Role of Wearables in Monitoring

Some clinicians now use consumer actigraphy devices (such as wrist-worn accelerometers) to document circadian rest-activity patterns before and during treatment. While not yet a standard-of-care requirement, actigraphy data can confirm the phase delay expected in SAD and track treatment response objectively.

Evidence-Based Treatments for Seasonal Depression

Treatment options fall into four categories: light therapy, pharmacotherapy, psychotherapy, and lifestyle modification. Most guidelines recommend combining at least two approaches for moderate-to-severe presentations.

Light Therapy: The Bedrock Treatment

A 10,000-lux fluorescent or LED light box used for 20 to 30 minutes each morning is the most-studied single intervention for winter SAD. A meta-analysis by Golden et al. Published in the American Journal of Psychiatry (N=332 across 8 RCTs) found light therapy produced a pooled effect size of 0.84 compared with dim-light placebo, comparable in magnitude to antidepressant pharmacotherapy for non-seasonal MDD (15).

Timing matters. Morning use phase-advances the circadian clock; evening use may worsen phase delay. The light box should be positioned 16 to 24 inches from the face, never stared at directly. Most patients notice improvement within one to two weeks.

Practical specifications for light therapy:

• Intensity: 10,000 lux at the eye
• Spectrum: full-spectrum white light or cool-white; UV-filtered devices preferred for ocular safety
• Duration: 20 to 30 minutes per session
• Timing: within 30 to 60 minutes of waking
• Season: begin in early October in Northern latitudes; continue through March or until natural light normalizes mood

Bupropion XL: The Only FDA-Approved Pharmacotherapy

Bupropion extended-release (Wellbutrin XL) carries the sole FDA-approved indication for the prevention of SAD. Two placebo-controlled trials (combined N=1,042) showed that bupropion XL 150 mg titrated to 300 mg daily, started six weeks before the patient's typical symptom onset, reduced the rate of SAD recurrence by approximately 44% versus placebo over one winter season (16). The FDA label was updated in 2006 to include this indication (17).

Common side effects include insomnia, dry mouth, and headache. Bupropion lowers the seizure threshold at doses above 450 mg/day and is contraindicated in patients with a history of seizure disorders or active eating disorders.

SSRIs and SNRIs

Selective serotonin reuptake inhibitors are widely used for SAD despite lacking an FDA-approved SAD indication. Sertraline, fluoxetine, and escitalopram have the most evidence in seasonal populations. A randomized trial comparing fluoxetine 20 mg with light therapy found equivalent remission rates (67% vs. 68%) after 8 weeks, with light therapy acting faster in the first two weeks (18).

Clinicians who prefer SSRIs for SAD generally initiate treatment in October and taper in April, mirroring the seasonal light cycle.

Cognitive Behavioral Therapy for SAD (CBT-SAD)

Rohan and colleagues at the University of Vermont developed a 12-session CBT protocol adapted specifically for SAD, targeting behavioral activation and thought restructuring around seasonal triggers. A randomized trial (N=177) published in the American Journal of Psychiatry found CBT-SAD produced equivalent first-season outcomes to light therapy, but showed a significant advantage over light therapy in preventing relapse across the following winter (46% relapse with CBT-SAD vs. 67% relapse with light therapy alone) (19).

CBT-SAD is particularly useful for patients who disqualify for bupropion (seizure or eating disorder history) or who cannot tolerate morning light therapy schedules.

Vitamin D Supplementation

Evidence for vitamin D supplementation as a standalone SAD treatment is mixed. A 2014 Cochrane systematic review found insufficient high-quality RCT data to recommend vitamin D for depression broadly (20). Supplementation to correct documented deficiency (serum 25(OH)D <20 ng/mL) is reasonable adjunctive practice, but should not replace light therapy or pharmacotherapy.

Exercise

Regular aerobic exercise has demonstrated antidepressant effects in multiple RCTs for non-seasonal MDD. For SAD specifically, a Norwegian cohort study (N=4,295) found that individuals exercising 60 minutes or more per week during winter months had significantly lower seasonal mood scores than sedentary peers, after adjusting for latitude and baseline depression (21). Exercise is best combined with outdoor daylight exposure when possible.

Combining Treatments: What the Evidence Supports

No large head-to-head trial has tested all four modalities simultaneously. The American Psychiatric Association's practice guideline for MDD states that combination therapy typically outperforms monotherapy for moderate-to-severe presentations (22). In clinical practice, most SAD specialists use the following tiered approach:

Tier 1 (mild SAD, GSS 11 to 16): Morning light therapy 10,000 lux for 20 to 30 minutes daily plus structured aerobic exercise three to five times per week. Begin in early October.

Tier 2 (moderate SAD, GSS 17 to 22, or Tier 1 failure after four weeks): Add bupropion XL 150 mg (titrate to 300 mg after one week) or an SSRI such as sertraline 50 to 100 mg. Continue light therapy concurrently.

Tier 3 (severe SAD, significant functional impairment, or repeated Tier 2 failures): Add CBT-SAD (12 sessions across 6 weeks) to pharmacotherapy and light therapy. Reassess bipolar spectrum disorder. Consider consultation with a psychiatrist.

Patients on Tier 2 or 3 regimens should schedule follow-up within four weeks of treatment initiation to assess response and tolerability.

When to Seek Care Immediately

Any depressive episode involving suicidal ideation, self-harm, or an inability to care for oneself warrants same-day psychiatric evaluation, regardless of season. SAD episodes can escalate to this severity, particularly in patients with comorbid anxiety or a prior history of suicide attempts. The 988 Suicide and Crisis Lifeline (call or text 988 in the U.S.) provides immediate support. The CDC maintains updated data on suicide rates by season, confirming that spring (not winter) represents the statistical peak for completed suicide in the U.S., a counterintuitive finding that underscores the need for continued vigilance as light returns (23).

Monitoring Treatment Response

Clinicians typically track SAD symptom response using serial PHQ-9 scores at baseline, at two weeks, and at four to six weeks after treatment starts. A PHQ-9 reduction of five or more points is considered a clinically meaningful response; a score below 5 indicates remission. Patients who do not achieve at least a 30% PHQ-9 reduction after four weeks of Tier 1 therapy should be stepped up promptly rather than waiting the full depressive season.

The American Psychiatric Association defines treatment-resistant depression as failure to respond to two adequate antidepressant trials of sufficient dose and duration (24). This threshold applies to SAD pharmacotherapy as well.

Special Populations

Adolescents

SAD occurs in adolescents, with school-based studies estimating prevalence between 1.7% and 5.5% in this age group. The SSRI fluoxetine has the most pediatric evidence for depressive disorders generally. Bupropion is not FDA-approved for depression in patients under 18. Light therapy carries no known safety concerns in this population and should be considered first-line (25).

Pregnant and Postpartum Patients

Light therapy is the preferred first-line option during pregnancy because it carries no known teratogenic risk. SSRIs in pregnancy require a careful risk-benefit discussion; the FDA's 2011 safety communication on SSRI use in late pregnancy and neonatal outcomes should inform shared decision-making (26).

Older Adults

Older adults metabolize antidepressants more slowly. Sertraline and escitalopram have favorable drug-interaction profiles in polymedicated older patients. Start at half the standard adult dose and titrate gradually. Light therapy remains safe and effective in this age group.